Oligonucleotide (siRNA) · Gene silencing: Coagulation factor XI (F11) · developed by City Therapeutics
CITY-FXI is a small interfering RNA (siRNA) given by subcutaneous injection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07430397 | Phase 1 | Factor V Leiden | Recruiting | CTY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Factor V LeidenProthrombin G20210AVenous Thromboembolism (VTE)
Updated Oct 25, 2026. Something wrong or missing? Report it on the CTY page.
See CTY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CTY catalysts and pipeline →